Treat Primary and Metastatic Liver Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-26

Study Completion Date

2022-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The use of Radiospheres in the management of intrahepatic cholangiocarcinoma is largely unknown and not reported in the medical literature. Methodist Dallas Medical Center has a large volume of IR procedures with Radioembolization and the investigators feel it is imperative to understand the outcomes, risks and benefits of the therapy in order to formulate recommendation to other centers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm

NCT01825824

Hepatocellular Carcinoma

UNKNOWN PHASE2

Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma

NCT02513199

Hepatocellular Carcinoma

COMPLETED PHASE2

Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer

NCT00019604

Liver Cancer Metastatic Cancer Unspecified Adult Solid Tumor, Protocol Specific

TERMINATED PHASE2

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

NCT01850667

Hepatocellular Carcinoma

COMPLETED PHASE2

Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma

NCT02729506

Hepatocellular Carcinoma

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A retrospective chart review of patients who have the diagnosis of intrahepatic cholangiocarcinoma. Only patients treated at MDMC are included and data will be obtained from Meditech and Epic. A non-identified database of cases with the diagnosis of intrahepatic cholangiocarcinoma already treated with radiospheres will be created and compared with cases treated by other means.

Intrahepatic cholangiocarcinoma is the second most common primary malignancy of the liver. The standard therapy has been resection but many cases are not resectable due to comorbidities or other poor surgical candidacy factors. Most of these patients end up getting chemotherapy which can be toxic and sometimes poorly tolerated. Intrarterial glass or resin radioembolization has been used and published from only 3 centers in the medical literature and it has been shown to be a reasonable alternative to the above options. At MDMC, this therapy has been used effectively and it is important to describe the investigator's experience.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intrahepatic Cholangiocarcinoma Liver Tumor Metastatic Cancer Metastatic Liver Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with the diagnosis of intrahepatic cholangiocarcinoma from January 2006 until April 2017 at Methodist Dallas Medical Center (MDMC)
* Patients 18 years old or older